The Indian government is determined to eliminate poor quality compliance in drug manufacturing. To achieve this, risk-based inspections are being conducted on drug manufacturing facilities. These inspections aim to verify if the facilities meet the required quality standards.
Health Minister Mansukh Mandaviya emphasized that there will be no compromise on drug quality. The government is fully committed to ensuring that drugs manufactured in India are of world-class quality.
The risk-based inspections primarily target high-risk facilities. These include those involved in manufacturing drugs for critical therapeutic areas like oncology and cardiovascular diseases.
Teams of experts from the Central Drugs Standard Control Organization (CDSCO) are responsible for carrying out the inspections. They will assess the facilities’ compliance with Good Manufacturing Practices (GMPs).
GMPs are international standards that govern the production of pharmaceutical products. Their purpose is to guarantee that drugs are manufactured in a safe and controlled environment, adhering to all quality standards.
The government’s crackdown on poor quality compliance in drug manufacturing is highly commendable. Ensuring the safety and effectiveness of the drugs we consume is crucial. The risk-based inspections play a vital role in upholding high-quality drug manufacturing in India.
